These data, and the fact that insulin resistance is associated with increased risk of breast cancer [125] and poor patient prognosis [126], suggest a possible role for PPAR-γ activators in either prevention or treatment of breast cancer patients. This evidence concerns the gene PPARG and breast cancer.